Analysis of polymorphic patterns in candidate genes in Israeli patients with prostate cancer.
BACKGROUND
The precise genes involved in conferring prostate cancer risk in sporadic and familial cases are not fully known.


OBJECTIVE
To evaluate the genetic profile within several candidate genes of unselected prostate cancer cases and to correlate this profile with disease parameters.


METHODS
Jewish Israeli prostate cancer patients (n = 224) were genotyped for polymorphisms within candidate genes: p53, ER, VDR, GSTT1, CYP1A1, GSTP1, GSTM1, EPHX and HPC2/ELAC2, followed by analysis of the genotype with relevant clinical and pathologic parameters.


RESULTS
The EPHX gene His113 allele was detected in 21.4% (33/154) of patients in whom disease was diagnosed above 61 years, compared with 5.7% (4/70) in earlier onset disease (P < 0.001). Within the group of late-onset disease, the same allele was noted in 5.5% (2/36) with grade I tumors compared with 18% (34/188) with grade II and up (P = 0.004). All other tested polymorphisms were not associated with a distinct clinical or pathologic feature in a statistically significant manner.


CONCLUSIONS
In Israeli prostate cancer patients, the EPHX His113 allele is seemingly associated with a more advanced, late-onset disease. These preliminary data need to be confirmed by a larger and more ethnically diverse study.
Figer
Arie
A
Institute of Oncology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
Friedman
Tal
T
Manguoglu
Ayse Esra
AE
Flex
Dov
D
Vazina
Amnon
A
Novikov
Ilia
I
Shtrieker
Avi
A
Sidi
A Ami
AA
Tichler
Thomas
T
Sapir
Einat Even
EE
Baniel
Jack
J
Friedman
Eitan
E
D000368:Aged; D000369:Aged, 80 and over; D005838:Genotype; D006801:Humans; D007585:Jews; D008297:Male; D008875:Middle Aged; D016133:Polymerase Chain Reaction; D011110:Polymorphism, Genetic; D011471:Prostatic Neoplasms / Q000235:genetics*